Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Forward Pharma (FWP) Halted LUDP; Shares Down 19%
January 29, 2018 11:20 AM ESTForward Pharma (NASDAQ: FWP) halted LUDP; Shares down 19% as trading resumes
... MoreBiogen (BIIB) PT Raised to $400 at Oppenheimer
January 26, 2018 6:46 AM ESTOppenheimer raised its price target on Biogen (NASDAQ: BIIB) to $400.00 (from $380.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "BIIB shares outperformed yesterday (+2.1% vs. NBI +0.7% and S&P 500 +0.1%) on strong 4Q17 financial results and confidence expressed by management regarding execution on key... More
Biogen (BIIB) PT Raised to $408 at Cowen
January 25, 2018 1:12 PM ESTCowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.
Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.
... MoreBiogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook
January 25, 2018 6:31 AM EST(Updated - January 25, 2018 6:33 AM EST)
Biogen (NASDAQ: BIIB) reported Q4 EPS of $5.26, $0.19 worse than the analyst estimate of $5.45. Revenue for the quarter came in at $3.31 billion versus the consensus estimate of $3.08 billion.
GUIDANCE:
Biogen sees FY2018 EPS of $24.20-$25.20... More
